Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.14 USD | -1.72% | -0.87% | -35.96% |
Mar. 14 | Transcript : Protalix BioTherapeutics, Inc., 2023 Earnings Call, Mar 14, 2024 | |
Mar. 14 | Protalix BioTherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Financials (USD)
Sales 2024 * | 74.06M | Sales 2025 * | 127M | Capitalization | 83.58M |
---|---|---|---|---|---|
Net income 2024 * | 17M | Net income 2025 * | 70M | EV / Sales 2024 * | 1.13 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 0.66 x |
P/E ratio 2024 * |
5.43
x | P/E ratio 2025 * |
1.41
x | Employees | 208 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.27% |
Latest transcript on Protalix BioTherapeutics, Inc.
1 day | -1.72% | ||
1 week | -0.87% | ||
1 month | -5.79% | ||
3 months | -21.38% | ||
6 months | -38.38% | ||
Current year | -35.96% |
Managers | Title | Age | Since |
---|---|---|---|
Dror Bashan
CEO | Chief Executive Officer | 57 | 19-06-29 |
Eyal Rubin
DFI | Director of Finance/CFO | 48 | 19-07-21 |
Yael Hayon
CTO | Chief Tech/Sci/R&D Officer | 41 | 20-07-04 |
Members of the board | Title | Age | Since |
---|---|---|---|
Pol Boudes
BRD | Director/Board Member | 67 | 19-11-30 |
Gwen Melincoff
BRD | Director/Board Member | 72 | 19-11-30 |
Aharon Schwartz
BRD | Director/Board Member | 80 | 14-10-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 34 M€ | +2.67% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-03 | 1.14 | -1.72% | 231,575 |
24-05-02 | 1.16 | -4.13% | 218,874 |
24-05-01 | 1.21 | +6.14% | 355,268 |
24-04-30 | 1.14 | -5.00% | 384,188 |
24-04-29 | 1.2 | +4.35% | 667,963 |
Delayed Quote Nyse, May 03, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-35.96% | 83.58M | |
+25.69% | 47.9B | |
+46.90% | 41.42B | |
-3.46% | 40.7B | |
-6.20% | 28.92B | |
+9.17% | 25.55B | |
-20.42% | 19.27B | |
+0.17% | 12.15B | |
+28.07% | 12.14B | |
-1.24% | 11.99B |
- Stock Market
- Equities
- PLX Stock